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Abstract 
Background: Microalbuminuria (MAU) is defined as an urinary albumin excretion rate between 20–200 mg/l or 
30–300 mg/day. It is a surrogate marker for endothelial dysfunction and is independently associated with athero‑
sclerotis in diabetic and in non‑diabetic patients. We assessed the prevalence of MAU in non‑diabetic patients who 
presented with UA/NSTEMI and the relation of MAU to the severity of coronary artery disease in patients at a cardiac 
care center in Iraq.
Methods: Seventy non‑diabetic patients referred to the Iraqi Center for Heart Disease, Baghdad, between Novem‑
ber 1st 2010 and June 1st 2011 with the diagnosis of UA/NSTEMI were included in this study. Physical examination, 
ECG and echocardiography were performed on all patients. TIMI (“Thrombolysis in Myocardial Infarction”) risk score 
was obtained. Urine samples were collected and sent for quantitative determination of MAU. All patients underwent 
diagnostic coronary angiography. Data are give as mean (quantitative and percent) ± SD.
Results: Fifty‑three men (76 %) and 17 (24 %) women (mean age 56 ± 12 years) were investigated. Overall 37 (53 %) 
individuals presented with arterial hypertension and 41 (59 %) with a history of smoking. 58 patients (83 %) had 
ischemic ECG changes (defined as ST segment depression more than 1 mm from baseline, and/or T wave inversion), 
52 (74 %) had echocardiographic findings indicative of ischemia (defined as segmental wall motion abnormalities). 
Twenty‑one (30 %) patients tested positive for MAU. There was a significant correlation of echocardiographic signs of 
ischemia and MAU, (n = 20 (38 %), p < 0.01). There was a clear relationship between MAU and TIMI risk score. Addi‑
tionally, MAU was more common in patients with multivessel coronary artery disease (CAD) (p < 0.001). There was no 
statistically significant correlation between MAU and mean age, sex, smoking, and blood pressure.
Conclusion: In this analysis of patients with UA/NSTEMI we found a strong correlation of microalbuminuria with 
echocardiographic changes and findings in coronary angiography.
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Background
Microalbuminuria (MAU) is a common phenomenon in 
patients with cardiovascular disease worldwide. MAU 
is defined as an urinary albumin excretion rate between 
20–200 mg/l or 30–300 mg/day. It can also be defined as 
persistent excretion of albumin in the urine at rates that 
are above normal range but below values detected by 
conventional methods including ordinary dipsticks [1]. 
In clinical practice MAU is used to evaluate renal impair-
ment in patients suffering from hypertension and in 
diabetic patients. MAU is closely associated with cardio-
vascular risk factors such as age, smoking, hypertension, 
diabetes, dyslipidemia and lack of physical activity [2–4].
In healthy individuals, the normal range for urinary 
albumin excretion rate is less than 30  mg/day. Urinary 
albumin excretion rate is known to increase with exer-
cise, oral protein intake, urinary tract infection, and 
pregnancy. Albumin excretion is, on average, 25 % higher 
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during the day than at night, with 40 % day to day vari-
ation. Albuminuria of 300  mg/day or more indicates 
nephropathy.
Data from several studies over the last two decades 
have demonstrated that MAU is not only a predictor of 
diabetic complications but also a powerful independent 
risk factor for coronary artery disease (CAD), moreover, 
MAU predicts development of ischemic cardiovascular 
events related to the development of atherosclerosis [5].
Several pathophysiological mechanisms as to how 
MAU may be related to the development of atheroscle-
rotic vascular disease, have been proposed. The currently 
accepted mechanism primarily involves local injury to 
vascular smooth muscle cells and endothelium leading to 
cell proliferation and increase in vascular permeability [6, 
7].
Prevalence of MAU
The prevalence of MAU among non diabetic individu-
als with arterial hypertension ranges from 5 to 40  %. A 
variety of factors are responsible for this high variabil-
ity: quality of blood pressure control and associated lipid 
abnormalities, patient selection and inclusion criteria 
biases such as age, race, coexisting renal disease, tech-
niques used for detection of MAU, sampling size, and day 
to day variability of albumin excretion [7].
Pathophysiology
The exact pathophysiology as to how MAU contributes 
to or accelerates atherosclerosis remains to be clarified. 
Current understanding suggests that mechanisms of vas-
cular injury associated with MAU differ between those 
with or without DM but who also have hypertension 
[8–10]. People with MAU have an elevated transcapillary 
escape rate of albumin. They also have clusters of other 
metabolic and non metabolic risk factors associated with 
CVD such as arterial hypertension, dyslipidemia, and 
insulin resistance [11, 12].
In persons with MAU without DM, an increase in vas-
cular permeability is caused by alterations in the extra-
cellular matrix; this contributes to the development of 
endothelial dysfunction which promotes lipid influx into 
the vessel wall causing atherosclerotic changes [8].
In many acute and chronic illnesses, MAU is associated 
with increased vascular permeability as the final common 
pathway involving complement activation and activation 
of macrophages, neutrophil granulocytes, and endothe-
lial cells via a variety of inflammatory mediators [9].
In addition to systemic vascular alterations, individu-
als with DM develop local injury at the level of the glo-
merular membrane. As a consequence of renal albumin 
losses vascular permeability increases and strain is put on 
the liver to compensate for these losses with an increased 
albumin synthesis [8].
However, the role of albumin in the pathogenesis of 
vascular disease in non-diabetic individuals could be dis-
tinct from those with diabetes: The glycation of albumin 
in diabetes transforms it into an antigenic molecule that 
initiates a variety of cellular and immune reactions, such 
as activation of polymorphonuclear leukocytes. Addi-
tionally, there is direct injury of glomerular membrane 
selectivity [13].
In summary pathophysiological processes associated 
with MAU are manifold: Local changes in the kidneys 
such as increased intraglomerular capillary pressure, 
increased shunting of albumin through glomerular mem-
brane pores and loss of glomerular membrane charge; 
systemic changes include activation of inflammatory 
mediators, increased transcapillary escape rate of albu-
min and vascular endothelial dysfunction.
Microalbuminuria and coronary artery disease
MAU reflects widespread vascular disease and is associ-
ated with the presence of unfavorable risk profile and tar-
get organ damage, especially in DM.
Major risk factors for coronary artery disease in the context 
of MAU
Hypertension
Several studies have shown that the amount of MAU pre-
sent in a given individual is proportional to the systolic, 
diastolic, and mean blood pressure as measured by either 
clinic or 24 h ambulatory blood pressure monitoring [11, 
14]. Circadian blood pressure abnormalities, as seen in 
(non dippers) who are known to be at high risk for coro-
nary artery disease, have also been described in individu-
als with MAU.
Men with MAU showed a higher relative risk of having 
an elevated systolic blood pressure compared to women 
with MAU. Furthermore the association of MAU and 
hypertension in diabetics is greater than in non diabetics 
[15].
Hyperinsulinemia
Both hyperinsulinemia and MAU have been shown to 
increase CVD risk in non-diabetics. This is even more 
true, if they coincide with other risk factors for athero-
sclerosis such as arterial hypertension, dyslipidemia, and 
obesity. Collectively, these risk factors are called syn-
drome X or cardiometabolic syndrome [16, 17].
Endothelial dysfunction
The endothelium produces components of extracellular 
matrix and a variety of proteins that play an important 
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role in vascular and renal function. Impaired endothe-
lial antithrombotic and vasodilatory properties are main 
factors in atherogenesis [13]. It has been proposed that 
defective endothelial permeability may be the origin of 
MAU in the general population, in those with arterial 
hypertension and among those with diabetes [10, 13].
Endothelial dysfunction seems to play a key role in 
non-diabetic glomerulosclerosis and atherosclerosis. 
Increased permeability of the endothelium allows athero-
sclerotic lipoprotein particles (oxidized LDL and others) 
to penetrate into the vessel wall and promote the devel-
opment of atherosclerotic plaques [10, 13].
MAU is also associated with biochemical indices of 
endothelial dysfunction, such as an increased von-Wille-
brand-Factor (VWF) and increased platelet adhesive-
ness. Higher levels of VWF were found in individuals 
with MAU and a direct correlation between these two 
variables was described. Other biochemical indices 
of endothelial dysfunction also associated with MAU 
include elevation in plasma concentrations of angioten-
sin II, tissue type plasminogen activator inhibitor-1, and 
endothelin-1 [13]. A greater amount of MAU not only 
represents endothelial damage but is also associated with 
an adverse cardiovascular prognosis [18].
Dyslipidemia
Several studies have shown an increased association 
between MAU and abnormalities in serum lipoproteins. 
These lipid abnormalities include low levels of HDL as 
well as high levels of LDL, total triglycerides, and lipo-
protein a. The most consistent association between lipo-
protein abnormalities and MAU is a low level of HDL 
[11, 19].
Clinical implications
The presence of MAU is of great diagnostic value since 
MAU represents a very sensitive manifestation of abnor-
mal vascular permeability. Its applications as a marker of 
target organ damage from cardiovascular disease include 
risk assessments, evaluation of disease severity and prog-
nosis [10].
From the available data, measurement of MAU is a 
very sensitive tool in the presence of inflammatory pro-
cesses including coronary artery disease and other acute 
inflammatory states, such as trauma, sepsis and surgery. 
The amount of MAU is proportional to the severity of the 
condition [12]. Ischemia and reperfusion are other condi-
tions that follow this rule [10].
MAU is also detected in the presence of an acute coro-
nary syndrome or peripheral vascular disease, it is pro-
portional to the severity of the infarct size or claudication 
[20, 21].
Early identification of MAU may influence the aggres-
siveness of management and ultimately the outcome of 
the disease.
Patients and methods
In this study 70 patients were admitted to the coronary 
care unit of the Iraqi Center for Heart disease, Baghdad, 
with the diagnosis of UA/NSTEMI between November 
1st, 2010 and June 1st, 2011. Twenty healthy persons 
served as a control group.
Patients with DM, STEMI, chronic stable angina, uri-
nary tract infection, and macroalbuminuria by urinary 
dipstick were excluded from the study.
A detailed medical history, thorough clinical exami-
nation with particular attention to the cardiovascular 
system, ECG and echocardiography were performed in 
each patient. The study complied with the provisions of 
the Declaration of Helsinki regarding investigations in 
humans, and was approved by local ethic committees 
(Ministry of Health, Republic of Iraq, Medical City) and 
written informed consent was obtained for all patients.
TIMI risk score for UA/NSTEMI was obtained for all 
patients. TIMI risk score identifies seven independent 
risk factors for UA/NSTEMI [22]. (Given one point for 
each factor, scores from 0 to 7):
1. Age older than 65 years.
2. Equal or more than 3 CAD risk factors.
3. Documented CAD at catheterization (more than 
50 % stenosis).
4. ST-segment deviation more than 0.5 mm from pre-
senting ECG.
5. Equal or more than 2 anginal episodes in prior 24 h.
6. Aspirin within prior week.
7. Elevated cardiac biomarkers.
A morning urine sample was collected from each 
patient. Macroalbuminuria was excluded with ordinary 
urinary dipstick testing [23]. Urinary tract infection was 
included by genitourinary examination. The probes were 
centrifuged, the precipitant was discarded and the super-
natant stored at −20 °C. MAU was tested in all samples 
simultaneously by immunometric enzyme immunoassay 
for the quantitative determination of MAU [24] by a kit 
from ORGENTEC diagnostika GmbH, Mainz, Germany.
In studies with urine samples from healthy individu-
als a range of albuminuria between 0 and 25 mg/ml has 
been established. Values above this range are considered 
pathological.
Coronary angiography was performed in all patients. 
Lesions >70 % stenosed were defined as significant.
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Statistical Package for Social Science (SPSS 14) was 
used for data storage and analysis. Data are give as mean 
(quantitative and percent)  ±  SD, associations between 
different variables were analyzed using Chi Square test. A 
p value ≤ 0.05 was considered to be significant.
Control group
20 age and sex matched individuals without hypertension 
or diabetes (10 men, 10 women) served as control. Out of 
these 5 (25 %) had a smoking history (4 men, 1 woman).
Results
Seventy patients were included in this study, mean age 
56  years ±  12 (range 26–89). Patient characteristics are 
shown in Table 1. MAU test was positive in 21 (30 %) of 
patients from the studied sample. Among patients with a 
positive MAU test (n = 21), the mean age was 55 years 
(Table 2). Specific differences in gender and cardiovascu-
lar risk factors as smoking and hypertension are shown 
in Tables 3, 4 and 5 respectively. Patients with ischemic 
changes in the ecg (as defined above) were more likely 
being MAU positive (32 versus 68  %) compared to 
patients without ecg changes (non-ischemic; 17 versus 
83  %) (Table  6). The same we were able to find in the 
echo findings, even reaching here statistical significance 
(p < 0.001) (Table 7).
Patients tested MAU-positive had either intermediate 
or high TIMI risk scores (as shown in Table 8). Further-
more MAU positive patients had more diseased ves-
sels. Statistic comparison between 2 groups according 
to MAU status considered highly significant, p  <  0.001 
(Table  9). 
In patients tested positive, the level of MAU ranged 
from 25.5 to 40.6  mg/ml, with cutoff point at microal-
buminuric level of 29  mg/ml, above cutoff point, none 
of patients with 1-VD, 2 (33 %) with 2-VD, and 13 (93 %) 
with 3-VD, while below the cutoff point, one patient 
(100 %) had a 1-VD, 4 (67 %) a 2-VD, and 1 (7 %) a 3-VD 
respectively, p = 0.01 (Table 10).
Table 1 Demographical characteristics of  studied popula-
tion
Variables No. (%)
Age (mean ± SD) 56.51 year ± 12.85
Men 53 (76 %)
Women 17 (24 %)
Smoker 41 (59 %)
Hypertension 37 (53 %)
Ischemic ECG changes 58 (83 %)
Ischemic ECHO finding 52 (74 %)
Table 2 Relation between mean age and MAU
P value = 0.8
1 N Mean(year) SD
−ve group 49 56.48 12.57
+ve group 21 55.71 12.02




Men 17 (32 %) 36 (68 %) 53 (100 %)
women 4 (24 %) 13 (76 %) 17 (100 %)




Smoker 12 (29 %) 29 (71 %) 41 (100 %)
Non‑smoker 9 (31 %) 20 (69 %) 29 (100 %)




Hypertensive 8 (22 %) 29 (78 %) 37 (100 %)
Non hypertensive 13 (39 %) 20 (61 %) 33 (100 %)




Ischemic changes 19 (32 %) 39 (68 %) 58 (100 %)
Non‑ischemic 2 (17 %) 10 (83 %) 12 (100 %)




Ischemic finding 20 (38 %) 32 (62 %) 52 (100 %)
Non‑ischemic 1 (6 %) 17 (94 %) 18 (100 %)
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All individuals in the control group had a negative 
MAU test (1.3–9.8 mg/ml).
Discussion
Several studies have implicated MAU as a risk factor for 
cardiovascular disease, particular in diabetic patients 
[25–27]. Cardiovascular disease leads to acute coronary 
syndrome as unstable angina (UA) and non-ST-segment 
elevation MI (NSTEMI). In this study MAU was detected 
in 21 (30 %) out of 70 non-diabetic patients, admitted to 
the Iraqi Center for Heart disease, Baghdad with a diag-
nosis of UA/NSTEMI. A similar result was obtained by 
Klausen et al., who found that MAU is a strong determi-
nant of coronary artery disease and death independently 
of age, sex, hypertension, DM, renal function, and lipid 
profile [28].
In our cohort we found no significant correlations of 
MAU with age, sex, smoking, and arterial hypertension. 
Smoking is a recognized cardiovascular risk factor, and 
it may be also related to MAU. In our study, MAU was 
more common in smokers than in non-smokers. Similar 
results were obtained by Jaun-Manuel Guizer [29], while 
Charles et al. could not confirm this finding [30].
Although several authors have reported the associa-
tion between high systolic blood pressure and MAU [33, 
34], in the present investigation, we were not able to see 
a similiar association in our study. A similar result was 
obtained by Klausen, who found that MAU is a predictor 
of coronary artery disease, irrespective of other risk fac-
tors including hypertension [30].
The prognostic value of MAU for CVD was first estab-
lished in patients with DM  [31, 32]. In non-diabetic 
subjects, the result from several studies have indicated 
that MAU is a marker of cardiovascular risk, more over, 
several studies have demonstrated that MAU is an inde-
pendent predictor of cardiovascular morbidity and mor-
tality in non-diabetic populations [33, 34].
In our study, MAU was more common in patients with 
ischemic ECG changes than in those without. Addition-
ally, there was a significant correlation with wall motion 
abnormalities as an echocardiographic sign of ischemia 
(p < 0.001). These findings add to results of Diercks et al., 
who described an increase in mortality in the subset of sub-
jects with both ST-T segment depression and MAU [35].
It has been postulated that MAU indicates increased 
vascular endothelial permeability not restricted to renal 
vessels. This could promote foam cell formation and 
atherogenesis by increased leakage of lipoprotein parti-
cles into the vessel wall, an increased transcapillary albu-
min excretion rate, an increased plasma level of VWF, 
and an attenuated endothelium dependent response to 
vasodilator stimuli in subjects with MAU [36]. Therefore 
individuals with ST-T segment changes in addition to 
MAU could have an increased risk of enhanced progres-
sion of atherosclerosis and subsequent mortality.
The ability of MAU to predict adverse cardiovascu-
lar events is not restricted to high risk populations. In a 
low risk population for CVD, this fact was supported by 
Hillege et  al. They demonstrated that MAU can predict 
CVD and non-CVD mortality in a general population 
[37].
Patients with high risk of adverse cardiovascular events 
as measured by the TIMI risk score were more likely to 
be MAU-positive compared to patients with low cardio-
vascular risk (Table 8).
A significant correlation between MAU and the sever-
ity of coronary artery disease as measured by the num-
ber of vessels with significant lesions was observed in this 
study. Patients with 2 or 3 vessels disease had a higher 
level of MAU than patients with single vessel disease, 
p < 0.001.
Table 8 Relation between MAU and TIMI risk score
TIMI score MAU Total
+ve, n (%) −ve, n (%)
<2 (0) 16 (33 %) 16 (23 %)
3 (0) 26 (53 %) 26 (37 %)
4 11 (53 %) 6 (12 %) 17 (24 %)
5 7 (33 %) 1 (2 %) 8 (12 %)
>6 3 (14 %) (0) 3 (4 %)
Total 21 (100 %) 49 (100 %) 70 (100 %)





Single vessel 1 (3 %) 28 (97 %)
2 vessels 6 (26 %) 17 (74 %)
3 vessels 14 (78 %) 4 (22 %)
Table 10 Relation between  MAU level and  the number 




1 VD 1 (100 %) 0
2 VD 4 (67 %) 2 (33 %)
3 VD 1 (7 %) 13 (93 %)
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This study showed that by measuring MAU in non-
diabetic patients with UA/NSTEMI, we can predict the 
severity of CAD and the risk of adverse outcome.
Conclusion
In our study MAU was prevalent in patients with a diag-
nosis of UA/NSTEMI which is a marker of high risk 
CAD, regardless of other traditional risk factors for CVD.
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